Alligator Bioscience extends collaboration with Orion Corporation

As Alligator Bioscience makes headways with its clinical development of cancer immunotherapy mitazalimab, the company’s bispecific antibody technology RUBY is also turning heads.

Alligator has announced extending its collaboration with Orion Corporation for the discovery of a second novel bispecific antibody directed towards immuno-oncology targets. BioStock spoke with Alligator’s CEO Søren Bregenholt to learn more.